Biotech Values

[DewDiligence]

BMY:

If the first-line trial shows marginal or no efficacy, how likely are physicians to prescribe ipi for 2nd line?

Very likely, IMO. There are several cases where a cancer drug has shown efficacy in one line of therapy and failed to show efficacy in another line of therapy for the same tumor type. Every practicing oncologist ought to be familiar with this concept.